
|Videos|October 19, 2017
Dr. Brinda Emu Provides Insight into HIV Monoclonal Antibody Ibalizumab
Author(s)Contagion® Editorial Staff
Brinda Emu, MD, offers insight into the HIV monoclonal antibody ibalizumab.
Advertisement
Brinda Emu, MD, of the Infectious Diseases department at Yale University, offers insight into monoclonal antibody ibalizumab. Dr. Emu explains that the antiretroviral binds CD4—the primary receptor for HIV—and inhibits the viral entry process. Ibalizumab is active against all major HIV clades.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Pritelivir Improves Outcomes in Immunocompromised Patients With Refractory Herpes Simplex Virus
2
Measles Update: February 6, 2026
3
Antibiotics Deconstructed: IV Fosfomycin
4
HIV in the Black Community: Shifting from Stigma and Health Inequalities to Communication and Care Initiatives
5

































































































































